Prostate Cancer Clinical Trial
Official title:
Psychosexual Support Following Prostate Cancer Surgery: Feasibility and Outcomes of a Couple-based Intervention
Verified date | December 2014 |
Source | University of Stirling |
Contact | n/a |
Is FDA regulated | No |
Health authority | United Kingdom: Research Ethics Committee |
Study type | Interventional |
Even with careful prostate surgery, men find it difficult to have an erection. Our previous
research shows that couples are not often supported to cope with the effects of surgery on
their sexual relationships. In this study, the investigators will design a way of supporting
couples, and test how well it works.
The investigators will decide what the support should include (e.g. duration, frequency and
timing of the support). The investigators will do this by looking at available literature on
the subject.
The investigators will recruit 68 couples to the study, half will receive standard care and
the other half will be invited to attend six sessions of psychosexual support with specially
trained professionals (trained by men affected by prostate conditions and a cancer/couple
support specialist). Before and after the support, men and their partners will be asked to
complete questionnaires which measure quality-of-life, emotional needs, and their
relationship. The investigators will ask the couples to fill out the questionnaires again
six-months later to see if the support has long-term benefits. At the end of the study the
investigators will also interview 10 couples to find out their views of the support, and
another 10 couples about standard treatment.
When the investigators have tested this support, they expect to see men and their partners
tell us that their quality of life has improved, and they have higher satisfaction with
their relationship. The investigators will calculate the overall cost of providing this
support, and the benefits it has on reducing the need for other health-care services (like
GP use).
Status | Active, not recruiting |
Enrollment | 136 |
Est. completion date | August 2015 |
Est. primary completion date | February 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Score of =60 on EPIC (a signal of potency) - >11 weeks post-operative for PCa (to recruit people who have recovered from the immediate effects from surgery and begun to regain some functioning. Follow-ups are held at 6weeks, 12weeks, 6months from surgery, until no further follow-up is required). - Has a partner Exclusion Criteria: - Does not have a partner (this is a couple intervention, the study can therefore only include men with a partner). - Prognosis of =1year (Most men who have had recent surgery will have a good prognosis, consequently it is unlikely that many men will be excluded by this criteria.) - Unable to provide informed consent. - Residing in Dumfries and Galloway. The recruiting clinic sees patients from a wide catchment area. However to prevent excess burden on participants traveling to the intervention site in Edinburgh, the investigators will exclude those living in Dumfries and Galloway. - >2 years from surgery (since long term adaptation will have commenced). - Unable to communicate in English (this is a feasibility trial, if the study moves to a full scale trial in future then it will seek to include couples and interpreters/translators). |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care
Country | Name | City | State |
---|---|---|---|
United Kingdom | Western General Hospital | Edinburgh | Lothian |
Lead Sponsor | Collaborator |
---|---|
University of Stirling | Prostate Cancer UK |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | EPIC (Expanded Prostate cancer Index Composite) | EPIC is a quality of life tool used in prostate cancer studies, focused on physical and sexual outcomes. It is validated with population norms | 6months | No |
Secondary | HADS (Hospital Anxiety and Depression Scale) | the HADS has two scales: one anxiety and one depression. It is validated with population norms | 6months | No |
Secondary | SCORE15 (systemic core outcome measure) | SCORE15 is an index of Family Function and Change, with 15 items. | 6months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |